Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study.

Takao Katoh Hidehiro Kakizaki Kyu-Sung Lee Kota Ishida Daisuke Kato Osamu Yamamoto Jar Jar Jong Budiwan Sumarsono Satoshi UnoOsamu Yamaguchi

Published in: Lower urinary tract symptoms (2020)

Cardiovascular-related adverse events were uncommon in both treatment groups. Mirabegron is a well-tolerated add-on therapy to tamsulosin in Japanese and Korean males with residual overactive bladder symptoms.

Keyphrases

lower urinary tract symptoms
benign prostatic hyperplasia
stem cells
depressive symptoms
drug induced